中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 12
Dec.  2018
Turn off MathJax
Article Contents

Effect of probiotics in treatment of nonalcoholic fatty liver disease: A Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2018.12.023
Research funding:

 

  • Published Date: 2018-12-20
  • Objective To systematically analyze the value of probiotics in the treatment of nonalcoholic fatty liver disease (NAFLD) .Methods PubMed, The Cochrane Library, Embase, Medline, CNKI, VIP, and Wanfang Data were searched for randomized controlled trials (RCTs) on probiotics in the treatment on NAFLD published before December 2017. Secondary screening was performed for retrieval results, the risk of bias of the studies included was evaluated, and related data were extracted. Rev Man 5. 3 was used for the meta-analysis.Results A total of 11 RCTs with 599 NAFLD patients were included. The results showed that probiotics significantly improved the levels of alanine aminotransferase (mean difference [MD]=-15. 23, 95% confidence interval [CI]:-19. 63 to-10. 82, P < 0. 000 01) , aspartate aminotransferase (MD =-17. 08, 95% CI:-24. 23 to-9. 92, P < 0. 000 01) , gamma-glutamyl transpeptidase (MD =-20. 49, 95%CI:-26. 23 to-14. 74, P < 0. 000 01) , triglyceride (MD =-0. 12, 95% CI:-0. 24 to-0. 01, P = 0. 04) , total cholesterol (MD =-0. 33, 95% CI:-0. 56 to-0. 11, P = 0. 003) , high-density lipoprotein (MD =-0. 07, 95% CI:-0. 14 to-0. 01, P = 0. 03) , tumor necrosis factor-α (MD =-0. 38, 95% CI:-0. 52 to-0. 24, P < 0. 000 01) , and homeostasis model assessment of insulin resistance (MD =-0. 39, 95% CI:-0. 53 to-0. 24, P < 0. 000 01) . However, probiotics had no significant effect on body mass index (MD =-0. 73, 95% CI:-1. 91 to 0. 46, P = 0. 23) and low-density lipoprotein (MD =-0. 30, 95% CI:-0. 60 to 0. 01, P = 0. 06) .Conclusion Probiotics can significantly reduce the levels of liver aminotransferases, blood lipids, inflammatory factors, and insulin resistance in patients with NAFLD and thus exerts a certain therapeutic effect on NAFLD.

     

  • loading
  • [1] Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association. Guidelines for management of non-alcoholic fatty liver disease[J]. J Clin Hepatol, 2010, 26 (2) :120-124. (in Chinese) 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].临床肝胆病杂志, 2010, 26 (2) :120-124.
    [2] YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64 (1) :73-84.
    [3] MIELE L, VALENZA V, La TORRE G, et al. Increased intestinal permeability and tight junction alterations in non-alcoholic fatty liver disease[J]. Hepatology, 2009, 49 (6) :1877-1887.
    [4] National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expen Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol, 2018, 34 (5) :947-957. (in Chinese) 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南 (2018年更新版) [J].临床肝胆病杂志, 2018, 34 (5) :947-957.
    [5] SHUAI T, TIAN X, WANG XT, et al. A brief introduction of Jadad algorithm of interpreting discordant Meta analyses[J]. Chin J Evidbased Med, 2016, 16 (4) :492-496. (in Chinese) 帅婷, 田旭, 王新田, 等.冲突性Meta分析评价方法:Jadad法则简介[J].中国循证医学杂志, 2016, 16 (4) :492-496.
    [6] SEPIDEH A, KARIM P, HOSSEIN A, et al. Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease:A double-blind randomized clinical trial[J]. J Am Coll Nutr, 2016, 35 (6) :500-505.
    [7] ALISI A, BEDOGNI G, BAVIERA G, et al. Randomized clinical trial:The beneficial effects of VSL#3 in obese children with nonalcoholic steatohepatitis[J]. Aliment Pharmacol Ther, 2014, 39 (11) :1276-1285.
    [8] ALLER R, de LUIS DA, IZAOLA O, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients:A double blind randomized clinical trial[J]. Eur Rev Med Pharmacol Sci, 2011, 15 (9) :1090-1095.
    [9] ESLAMPARAST T, POUSTCHI H, ZAMANI F, et al. Synbiotic supplementation in nonalcoholic fatty liver disease:A randomized, double-blind, placebo-controlled pilot study[J]. Am J Clin Nutr, 2014, 99 (3) :535-542.
    [10] FAMOURI F, SHARIAT Z, HASHEMIPOUR M, et al. Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents[J]. Pediatr Gastroenterol Nutr, 2017, 64 (3) :413-417.
    [11] MALAGUARNERA M, VACANTE M, ANTIC T, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis[J]. Dig Dis Sci, 2012, 57 (2) :545-553.
    [12] VAJRO P, MANADATO C, LICENZIATI MR, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity related liver disease[J]. J Pediatr Gastroenterol Nutr, 2011, 52 (6) :740-743.
    [13] WONG VW, WON GL, CHIM AM, et al. Treatment of nonalcoholic steatohepatitis with probiotics. Aproof-of-concept study[J].Ann Hepatol, 2013, 12 (2) :256-262.
    [14] SHI BS. Effect of live combined Bifidobacterium and Lactobacillus tablets in improving nonalcoholic fatty liver disease[J]. Chin J Prev Contr Chron Dis, 2017, 25 (5) :387-390. (in Chinese) 史保生.双歧杆菌乳杆菌三联活菌片对非酒精性脂肪性肝病的改善作用[J].中国慢性病预防与控制, 2017, 25 (5) :387-390.
    [15] YAO HX, CHEN WX, CHEN W, et al. Clinical study of probiotics in treatment of non-alcoholic fatty liver disease[J]. Chin J Gastroenterol and Hepatol, 2013, 22 (3) :221-223. (in Chinese) 姚惠香, 陈维雄, 陈玮, 等.益生菌治疗非酒精性脂肪性肝病的临床研究[J].胃肠病学和肝病学杂志, 2013, 22 (3) :221-223.
    [16] ZHAO QW, LYU DX. Probiotics for non-alcoholic fatty liver disease intervention effect[J]. China Mod Doct, 2016, 54 (8) :29-33. (in Chinese) 赵庆卫, 吕道仙.益生菌对非酒精性脂肪性肝病的干预作用[J].中国现代医生, 2016, 54 (8) :29-33.
    [17] LIU XY, KONG GM, QIAN F, et al. Advances in research on probiotics for the treatment of inflammatory bowel disease[J]. Clin J Med Offic, 2018, 46 (7) :840-842. (in Chinese) 刘心意, 孔桂美, 钱锋.益生菌治疗炎症性肠病研究进展[J].临床军医杂志, 2018, 46 (7) :840-842.
    [18] ZHAO WT, LIN M, JIAO XH, et al. Comparative study of probiotics combined with triple therapy in the treatment of Helicobacter pylori infection in both spouses[J]. Clin J Med Offic, 2018, 46 (2) :191-193. (in Chinese) 赵文涛, 林苗, 焦小红, 等.配偶双方感染幽门螺杆菌采用益生菌联合三联疗法进行同时治疗与单方治疗疗效对比研究[J].临床军医杂志, 2018, 46 (2) :191-193.
    [19] PAOLELLA G, MANDATO C, PIERRI L, et al. Gut-liver axis and probiotics:Their role in non-alcoholic fatty liver disease[J].World J Gastroenterol, 2014, 20 (42) :15518-15531.
    [20] CHANG Y, LI H. The role of gut microbiota in thedevelopment and progression of nonalcoholic steatohepatitis[J]. J Clin Hepatol, 2018, 34 (6) :1343-1346. (in Chinese) 常越, 李海.肠道菌群与非酒精性脂肪性肝炎发生发展的关系[J].临床肝胆病杂志, 2018, 34 (6) :1343-1346.
    [21] CHEN Z, HAN CK, PAN LL, et al. Serum alanine aminotransferase independently correlates with intrahepatic triglyceride contents in obese subjects[J]. Dig Dis Sci, 2014, 59 (10) :2470-2476.
    [22] SATOH H, SAIJO Y, YOSHIOKA E, et al. Helicobacter Pylori infection is a significant risk for modified lipid profile in Japanese male subjects[J]. Atheroscler Thromb, 2010, 17 (10) :1041-1048.
    [23] FEDERICO A, DALLIO M, GODOS J, et al. Targeting gut-liver axis for the treatment of non-alcoholic steatohe-patitis:translational and clinical evidence[J]. Transl Res, 2016, 167 (1) :116-124.
    [24] SHIDA K, NOMOTO K. Probiotics as efficient immunpotentiators:Translational role in cancer prevention[J]. Indian Med Res, 2013, 138 (5) :808-814.
    [25] FUKUDA S, TOH H, HASE K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate[J].Nature, 2011, 469 (7331) :543-547.
    [26] YAO XM, QU JG, LIN AB, et al. Effect of probiotics on non-alcoholic fatty liver disease[J]. J Int Pham Res, 2014, 41 (5) :548-551, 558. (in Chinese) 姚晓敏, 曲均革, 林爱斌, 等.益生菌作用治疗非酒精性脂肪肝[J].国际药学研究杂志, 2014, 41 (5) :548-551, 558.
    [27] BAI LM, ZHENG PY, ZHANG J, et al. Effects of cholesterollowering probiotics on the metabolism of bile acid in a rat model of non-alcoholic fatty liver disease[J]. Chin J Microbiol Immunol, 2016, 36 (2) :110-116. (in Chinese) 白利梅, 郑鹏远, 张军, 等.降脂益生菌对非酒精性脂肪肝大鼠胆汁酸代谢的影响及机制[J].中华微生物学和免疫学杂志, 2016, 36 (2) :110-116.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1508) PDF downloads(330) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return